The tyrosine kinase inhibitor (TKI) imatinib targets KIT and PDGFRA, offering significant therapeutic benefits in advanced gastrointestinal stromal tumors (GISTs). This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.